Lutetium Lu177 Edotreotide (ITM-11): A Comprehensive Monograph on a Novel Radiopharmaceutical for Neuroendocrine Tumors

Executive Summary

Lutetium Lu177 Edotreotide, also known by the development code ITM-11, is an investigational, small-molecule radiopharmaceutical agent representing a significant advancement in the field of peptide receptor radionuclide therapy (PRRT). It is designed for the targeted treatment of somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs), a heterogeneous group of malignancies for which therapeutic options remain limited. The drug is a complex radioconjugate, composed of the somatostatin analogue edotreotide (DOTATOC), the chelator DOTA, and the therapeutic beta-emitting radioisotope Lutetium-177 (177Lu). Its mechanism of action relies on the high-affinity binding of edotreotide to SSTRs, particularly subtype 2, which are densely expressed on the surface of many NET cells. Following binding, the agent is internalized, delivering a highly localized and cytotoxic dose of radiation that induces DNA damage and subsequent tumor cell apoptosis.

The clinical development of Lutetium Lu177 Edotreotide is spearheaded by two pivotal Phase III trials. The recently completed COMPETE trial (NCT03049189) evaluated its efficacy and safety in patients with Grade 1 and 2 gastroenteropancreatic NETs (GEP-NETs) against the approved standard-of-care mTOR inhibitor, everolimus. The trial successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS). Patients treated with Lutetium Lu177 Edotreotide experienced a median PFS of 23.9 months compared to 14.1 months for those receiving everolimus. Furthermore, the drug exhibited a favorable safety profile, with a lower incidence of treatment-related adverse events compared to the active comparator.

A second ongoing Phase III trial, COMPOSE (NCT04919226), is investigating the agent in patients with more aggressive, well-differentiated Grade 2 and 3 GEP-NETs against the best standard of care, including chemotherapy. Supported by Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA), the developer, ITM Isotope Technologies Munich SE, plans to submit a New Drug Application (NDA) in 2025. Based on the robust evidence from its clinical program, Lutetium Lu177 Edotreotide is poised to become a new standard of care in the management of GEP-NETs, offering a potent and well-tolerated targeted therapy for this patient population.

I. Molecular Profile and Pharmaceutical Characteristics

1.1 Chemical Structure and Composition

Lutetium Lu177 Edotreotide is a precisely engineered radioconjugate, a class of therapeutics that links a radioactive isotope to a targeting molecule to achieve selective delivery of radiation to cancer cells.[1] Its structure is a synergistic assembly of three distinct functional components: a targeting moiety, a stable chelator, and a therapeutic radionuclide.[3]

• Targeting Moiety: Edotreotide. The component responsible for tumor cell recognition is edotreotide, a synthetic cyclic peptide analogue of the natural hormone somatostatin.[1] Also known as-octreotide or TOC, edotreotide is derived from the well-established somatostatin analogue octreotide through the substitution of the amino acid tyrosine for phenylalanine at the third position in the peptide sequence.[1] This specific modification is critical for its high-affinity binding to somatostatin receptors, which are overexpressed on NET cells.[1]
• Chelator: DOTA. To stably incorporate the radioactive metal ion, edotreotide is conjugated to the bifunctional, macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, commonly known as DOTA.[1] DOTA forms an exceptionally stable complex with the Lutetium-177 ion, which is essential for therapeutic efficacy and safety. This high kinetic and thermodynamic stability ensures that the radionuclide remains firmly bound to the targeting peptide as it circulates throughout the body, preventing its premature release and subsequent accumulation in non-target tissues, such as bone, which would lead to unacceptable toxicity.[6]
• Therapeutic Radioisotope: Lutetium-177 (177Lu). The cytotoxic payload of the drug is the radioisotope Lutetium-177.[1] 177Lu is a lanthanide metal that decays with a physical half-life of approximately 6.7 days, emitting medium-energy beta ( β−) particles with a maximum energy of 0.49 MeV and a mean tissue penetration of 0.67 mm.[8] This decay profile is considered ideal for treating small- to medium-sized tumors, as the short path length of the beta particles localizes the radiation dose to the tumor while largely sparing adjacent healthy tissue.[8] A key feature highlighted by the developer, ITM, is the use of "no-carrier-added" (n.c.a.) 177Lu.[4] N.c.a. 177Lu possesses a higher specific activity (more radioactivity per unit of mass) and greater isotopic purity compared to "carrier-added" preparations.[9] This distinction is not merely technical; it implies that a therapeutic dose of radiation can be achieved with a smaller mass of the overall drug conjugate, which may enhance the therapeutic index by potentially reducing peptide-related side effects or allowing for a higher radiation dose to be delivered for the same peptide mass. In addition to its therapeutic beta emissions, 177Lu also emits low-energy gamma photons (113 keV and 208 keV).[8] These gamma emissions are not significantly cytotoxic but are suitable for imaging with standard nuclear medicine cameras (SPECT), allowing for post-administration visualization of drug distribution, confirmation of tumor uptake, and patient-specific radiation dosimetry calculations.[10]

1.2 Physicochemical Properties and Identifiers

For the precise and unambiguous identification of Lutetium Lu177 Edotreotide in scientific literature, clinical trial registries, and regulatory databases, a standardized set of chemical identifiers and properties is utilized. These are summarized in Table 1. The physicochemical properties, predicted by computational models, indicate that the molecule is a large, polar peptide conjugate with poor oral bioavailability, necessitating intravenous administration for systemic delivery.[12]

Table 1: Key Identifiers and Physicochemical Properties of Lutetium Lu177 Edotreotide

Property	Value	Source(s)
Generic Name	Lutetium Lu177 Edotreotide	12
DrugBank ID	DB17278	5
CAS Number	321835-55-6	5
UNII Code	RGO812Q0C8	5
Developer Code	ITM-11	3
Molecular Formula	C65​H89​LuN14​O18​S2​	5
Molecular Weight	1595.6 g/mol	5
Drug Type	Small Molecule, Radiopharmaceutical, Peptide Drug Conjugate	12
Synonyms	177Lu-DOTATOC,-TOC, Solucin, 177Lu-DOTA-Tyr3-octreotide	1
Hydrogen Bond Acceptor Count	23	12
Hydrogen Bond Donor Count	14	12
Polar Surface Area	488.88 A˚2	12
Predicted Oral Bioavailability	0	12

II. Pharmacodynamics: Targeted Radionuclide Therapy

2.1 Primary Mechanism of Action: SSTR Targeting

The therapeutic principle of Lutetium Lu177 Edotreotide is rooted in the targeted delivery of cytotoxic radiation, a strategy known as Peptide Receptor Radionuclide Therapy (PRRT).[2] The efficacy of this approach is contingent upon a key biological feature of its target malignancy: the high-density expression of somatostatin receptors (SSTRs) on the cell surface of well-differentiated neuroendocrine tumors.[10] While five subtypes of SSTRs exist, SSTR subtype 2 (SSTR2) is the most ubiquitously and densely expressed in GEP-NETs.[18]

The edotreotide component of the drug functions as a high-affinity agonist for SSTRs, particularly SSTR2 and SSTR5.[1] When administered intravenously, Lutetium Lu177 Edotreotide circulates in the bloodstream and acts as a molecular probe, selectively seeking out and binding to these receptors on NET cells throughout the body.[1] This specific binding event effectively concentrates the radiopharmaceutical at sites of disease, including both the primary tumor and distant metastases, while largely avoiding healthy tissues that express low levels of SSTRs.[2] The success of this targeting mechanism is a prerequisite for therapy, and patient eligibility for clinical trials is therefore dependent on the confirmation of SSTR-positivity on tumors, typically visualized using diagnostic SSTR-targeted PET imaging (e.g., with Gallium-68 DOTATATE).[3]

2.2 Cellular Internalization and Radionuclide-Induced Cytotoxicity

The therapeutic action of Lutetium Lu177 Edotreotide extends beyond simple cell-surface binding. Following the high-affinity interaction between edotreotide and the SSTR, the entire drug-receptor complex is actively transported into the tumor cell through a process called receptor-mediated endocytosis.[1] This internalization step is of paramount importance, as it effectively traps the radioactive 177Lu payload within the cancer cell, leading to prolonged retention and maximizing the cumulative radiation dose delivered to the cell's most vulnerable component: its nucleus.[1]

Once sequestered inside the cell, the 177Lu isotope undergoes beta decay.[2] The emitted beta particles, which are high-energy electrons, deposit their energy along a short path within the cell and its immediate vicinity.[3] This localized deposition of ionizing radiation generates a cascade of cytotoxic events, primarily through the formation of free radicals and reactive oxygen species (ROS) from intracellular water molecules.[6] These highly reactive molecules inflict widespread damage on cellular macromolecules, with the most critical target being nuclear DNA.[2] The radiation induces a spectrum of DNA lesions, including single-strand breaks (SSBs) and, most lethally, double-strand breaks (DSBs).[6] While cells possess DNA repair mechanisms, the high density of damage caused by the trapped radionuclide can overwhelm these systems. Unrepaired DSBs are catastrophic for the cell, triggering the activation of cell death pathways, most notably apoptosis, which leads to the elimination of the cancer cell and contributes to tumor regression and disease control.[6]

Furthermore, the physical properties of the beta particles emitted by 177Lu give rise to a "crossfire" effect.[19] Because the particles can travel up to a few cell diameters (1-2 mm), radiation from a single cell that has internalized the drug can also damage adjacent tumor cells that may not have bound the agent, thereby amplifying the anti-tumor effect within the tumor microenvironment. This dual mechanism of direct cell killing and a localized crossfire effect contributes to the potent antineoplastic activity of Lutetium Lu177 Edotreotide.

The gamma photons also emitted during 177Lu decay, while contributing negligibly to the therapeutic effect, provide an invaluable functional benefit. They allow for post-treatment imaging using SPECT cameras, enabling clinicians to visualize the biodistribution of the therapeutic agent in real-time.[10] This capability confirms that the drug has successfully targeted the tumors, allows for the calculation of absorbed radiation doses to both tumors and healthy organs (dosimetry), and can serve as an early indicator of treatment response.[10] This integration of therapy and diagnostics within a single agent exemplifies the "theranostic" paradigm, a cornerstone of modern precision nuclear medicine.[7]

III. Pharmacokinetics and Radiation Dosimetry

3.1 Preclinical and Clinical Pharmacokinetics

A comprehensive human pharmacokinetic (PK) profile for Lutetium Lu177 Edotreotide is not yet fully detailed in publicly available literature, as the complete data from its pivotal trials are pending publication. However, its PK properties can be reasonably inferred from preclinical studies, data on structurally similar radiopharmaceuticals, and the general principles governing peptide-based agents.

• Administration and Absorption: As a peptide-based drug, Lutetium Lu177 Edotreotide has negligible oral bioavailability and must be administered via intravenous infusion to achieve systemic circulation.[12]
• Distribution: Following intravenous administration, the drug is expected to distribute rapidly throughout the body. Its distribution is primarily governed by blood flow and the expression of SSTRs in various tissues. High uptake is observed in SSTR-positive tumors and in organs with physiological SSTR expression, such as the spleen, liver, and pituitary gland.[19] The kidneys are a major organ of both accumulation and elimination, representing a critical site for potential toxicity.[18] Preclinical studies in animal models using the related compoundY-DOTATOC confirmed this distribution pattern, particularly the significant renal uptake.[7]
• Metabolism and Elimination: Peptide radiopharmaceuticals like Lutetium Lu177 Edotreotide are not significantly metabolized by the hepatic cytochrome P450 enzyme system.[22] The primary route of clearance from the body is renal excretion.[19] Studies with the closely related drug, Lutetium Lu177 dotatate, show that approximately 65% of the administered dose is excreted in the urine within 48 hours.[19] A study of a different SSTR-targeted agent, [177Lu]Lu-satoreotide tetraxetan, reported a median terminal blood half-life of 127 hours, indicating a prolonged circulation time that allows for sustained tumor targeting before eventual clearance.[23]

3.2 Organ-Specific Dosimetry and Renal Protection

Dosimetry, the science of measuring the absorbed dose of ionizing radiation in tissues, is a fundamental component of PRRT development and clinical practice.[15] It is essential for optimizing the therapeutic window—maximizing the radiation dose to tumors while keeping the dose to critical healthy organs below established toxicity thresholds.[26]

• Organs at Risk: The two primary organs at risk of dose-limiting toxicity during PRRT are the kidneys and the bone marrow.[17] The kidneys are particularly vulnerable due to the glomerular filtration and subsequent tubular reabsorption of the peptide conjugate, which leads to prolonged retention of the radionuclide in the renal cortex.[7] The bone marrow is irradiated by the circulating radiopharmaceutical in the blood pool.[19]
• Renal Protection Strategy: The risk of nephrotoxicity is a well-established challenge in PRRT. To address this, the administration of Lutetium Lu177 Edotreotide is accompanied by the co-infusion of a specific amino acid solution containing L-lysine and L-arginine.[20] This intervention is not merely supportive care but an integral and indispensable part of the treatment regimen. The positively charged amino acids competitively inhibit the reabsorption of the radiopharmaceutical in the proximal tubules of the kidneys.[7] This competitive inhibition significantly reduces the amount of radiation absorbed by the kidneys, thereby preventing severe nephrotoxicity and allowing for the administration of a full therapeutic dose of the drug.[19] This strategy is a standard and essential practice across all SSTR-targeted PRRTs. The clinical trials for Lutetium Lu177 Edotreotide explicitly include this renal protection protocol as well as dosimetry assessments to monitor absorbed doses in real-time, ensuring patient safety.[25]

IV. Clinical Development and Efficacy in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

The clinical development program for Lutetium Lu177 Edotreotide is robust, anchored by two large-scale, randomized Phase III trials designed to establish its efficacy and safety across the spectrum of well-differentiated GEP-NETs. This two-pronged strategy, targeting both lower-grade (COMPETE) and more aggressive higher-grade (COMPOSE) tumors, reflects an ambitious plan to position the drug as a foundational therapy for this disease. A summary of these pivotal trials is provided in Table 2.

Table 2: Summary of Pivotal Phase III Clinical Trials for Lutetium Lu177 Edotreotide

Trial Name	NCT Identifier	Phase	Patient Population	Interventions	Primary Endpoint	Status
COMPETE	NCT03049189	III	Inoperable, progressive Grade 1/2 SSTR+ GEP-NETs	177Lu-Edotreotide vs. Everolimus	Progression-Free Survival (PFS)	Completed (Primary Completion Nov 2024) 21
COMPOSE	NCT04919226	III	Well-differentiated aggressive Grade 2/3 SSTR+ GEP-NETs	177Lu-Edotreotide vs. Best Standard of Care (Chemo or Everolimus)	Progression-Free Survival (PFS)	Active, not recruiting 20

4.1 The COMPETE Trial (NCT03049189): Efficacy in Grade 1 and 2 GEP-NETs

4.1.1 Study Design and Patient Demographics

The COMPETE trial was a prospective, randomized, controlled, open-label, multicenter Phase III study that served as the cornerstone for establishing the clinical benefit of Lutetium Lu177 Edotreotide.[21] The study enrolled 309 patients across Europe, the United States, Australia, and South Africa with inoperable, progressive, SSTR-positive, well-differentiated GEP-NETs of either gastroenteric or pancreatic origin, restricted to Grade 1 or 2 (Ki-67 proliferation index ≤20%).[21] This patient population represents a common clinical scenario where disease has progressed following initial therapies such as somatostatin analogues.

The trial's design was a direct head-to-head comparison against an active and approved standard of care. Patients were randomized in a 2:1 ratio to receive either:

• Experimental Arm (n=207): Lutetium Lu177 Edotreotide administered at a dose of 7.5 GBq via intravenous infusion every three months for a total of four cycles, with a mandatory co-infusion of a nephroprotective amino acid solution.[25]
• Control Arm (n=102): Everolimus, an oral mTOR inhibitor, administered at the standard dose of 10 mg daily until disease progression or for a maximum of 30 months.[25]

This ambitious design, challenging an established targeted therapy rather than a placebo or less active comparator, provides a high level of evidence. Its success represents a landmark achievement, being the first time a targeted radiopharmaceutical has demonstrated superiority over a targeted molecular therapy in a Phase III trial for this indication.[26]

4.1.2 Primary Endpoint Analysis: Progression-Free Survival

The COMPETE trial successfully met its primary endpoint, demonstrating that Lutetium Lu177 Edotreotide significantly prolongs progression-free survival (PFS) compared to everolimus.[11] The top-line results, presented in early 2025, showed a clinically meaningful and statistically significant benefit for the radiopharmaceutical arm. The key efficacy outcomes are detailed in Table 3. The data indicate that treatment with Lutetium Lu177 Edotreotide reduced the risk of disease progression or death by 33% compared to everolimus. The nearly 10-month improvement in median PFS is a substantial clinical benefit for this patient population.[32]

Table 3: Key Efficacy Outcomes from the COMPETE Trial (177Lu-Edotreotide vs. Everolimus)

Efficacy Endpoint	177Lu-Edotreotide Arm (n=207)	Everolimus Arm (n=102)	Hazard Ratio (95% CI)	p-value
Median Progression-Free Survival (PFS)	23.9 months	14.1 months	0.67 [0.48, 0.95]	0.022
Interim Median Overall Survival (OS)	63.4 months	58.7 months	0.78 [0.5, 1.1]	0.206
Data sourced from 11

4.1.3 Secondary Endpoint Analysis: Overall Survival and Response Rates

The analysis of overall survival (OS), a key secondary endpoint, is ongoing. The interim analysis, conducted as of January 21, 2025, showed a numerical trend in favor of Lutetium Lu177 Edotreotide, with a median OS of 63.4 months versus 58.7 months for everolimus.[11] However, this difference did not reach statistical significance (p=0.206).[25] This outcome is common in modern oncology trials where effective subsequent therapies are available. Patients in the everolimus arm who experienced disease progression were permitted to receive other treatments, including potentially PRRT, which can extend their survival and "confound" or dilute the observable OS benefit of the initial therapy.[14] For this reason, PFS is often considered the most robust measure of a drug's direct efficacy in this setting and is a well-accepted endpoint for regulatory approval.

Data regarding other secondary endpoints, including the objective response rate (ORR), are still being analyzed and are expected to be presented at future medical conferences.[26]

4.2 The COMPOSE Trial (NCT04919226): Investigating Efficacy in Aggressive Grade 2 and 3 GEP-NETs

Building on the success in lower-grade tumors, the COMPOSE trial is designed to evaluate Lutetium Lu177 Edotreotide in a population with a higher unmet medical need: patients with well-differentiated but aggressive Grade 2 and Grade 3 GEP-NETs (Ki-67 index 15-55%).[20] This Phase III study is evaluating the drug as a first- or second-line treatment option.[31]

The trial aims to randomize 202 patients in a 1:1 ratio to receive either Lutetium Lu177 Edotreotide or the "Best Standard of Care".[20] This comparator arm is pragmatic, allowing the treating physician to choose from several accepted standard therapies, including chemotherapy regimens (CAPTEM or FOLFOX) or the mTOR inhibitor everolimus.[31] The primary endpoint is PFS, and the study is currently active but no longer recruiting, with an estimated primary completion date of June 2027.[31] Positive results from COMPOSE would significantly broaden the potential role of Lutetium Lu177 Edotreotide, establishing its utility in higher-risk disease and positioning it as a targeted, and potentially less toxic, alternative to systemic chemotherapy.

4.3 Emerging Investigational Programs

The therapeutic application of Lutetium Lu177 Edotreotide is being explored beyond GEP-NETs, leveraging its SSTR-targeting mechanism.

• LEVEL (NCT05918302): An investigator-sponsored Phase III trial is underway to evaluate the drug in patients with neuroendocrine tumors of the lung and thymus, another area of unmet need with few approved therapies.[4] This trial also uses everolimus as the active comparator.[43]
• KinLET (NCT06441331): A Phase I trial is assessing the safety and pharmacokinetics of the drug in pediatric patients with SSTR-positive tumors, addressing the lack of approved PRRT options for this population.[4]

V. Comprehensive Safety and Tolerability Profile

5.1 Adverse Events Observed in the COMPETE Trial

The safety data from the Phase III COMPETE trial indicate that Lutetium Lu177 Edotreotide is a well-tolerated therapy, particularly when compared directly to the chronic daily administration of everolimus.[11] A key top-line finding was the lower overall incidence of treatment-emergent adverse events (TEAEs) related to the study drug in the Lutetium Lu177 Edotreotide arm. This favorable comparative safety profile, combined with superior efficacy, strengthens the drug's clinical value proposition. The intermittent dosing schedule of PRRT (four infusions over nine months) likely contributes to its better tolerability compared to the continuous exposure associated with daily oral everolimus.[21] A summary of the comparative safety is presented in Table 4.

Table 4: Comparative Safety Profile from the COMPETE Trial

Safety Parameter	177Lu-Edotreotide Arm	Everolimus Arm
Treatment-Emergent AEs related to study medication	82.5%	97.0%
Serious TEAEs of Note	1 case of Grade 2 Myelodysplastic Syndrome (MDS) reported	Data not specified
Overall Assessment	Well-tolerated, no unforeseen TEAEs reported, Favorable safety profile	N/A
Data sourced from 11

While a detailed breakdown of all adverse events from COMPETE is pending full publication, the expected side effects are consistent with the known class effects of PRRT. Based on extensive experience with Lutetium Lu177 dotatate, common acute and subacute side effects include nausea and vomiting (often related to the amino acid infusion), fatigue, decreased appetite, and abdominal pain.[44]

5.2 Hematologic and Renal Toxicity

The primary toxicities of concern with PRRT are related to radiation exposure of non-target organs.

• Hematologic Toxicity: Myelosuppression is the most common significant toxicity, resulting from irradiation of hematopoietic stem cells in the bone marrow.[17] This typically manifests as reversible, dose-dependent decreases in blood cell counts. In large studies of Lutetium Lu177 dotatate, the most frequent Grade 3-4 laboratory abnormality is lymphopenia (44%), followed by lower rates of increased GGT (20%), thrombocytopenia, anemia, and neutropenia.[47] These cytopenias are generally manageable with monitoring and, if necessary, dose delays or reductions.[48]
• Renal Toxicity: As discussed previously, the kidneys are a critical organ at risk. However, the mandatory co-infusion of a lysine- and arginine-containing amino acid solution has proven highly effective at mitigating nephrotoxicity.[28] Long-term follow-up of patients treated with Lutetium Lu177 dotatate has shown that clinically significant, permanent renal failure is a rare event when these protective measures are employed.[51] Nevertheless, patients with pre-existing moderate renal impairment should be monitored closely, as they may have slower clearance of the drug and thus increased radiation exposure.[22]

5.3 Long-Term Safety Considerations and Risk of Secondary Malignancies

The most serious long-term risk associated with the DNA-damaging mechanism of PRRT is the development of therapy-related secondary hematologic malignancies. In the COMPETE trial, one patient (out of 207) in the Lutetium Lu177 Edotreotide arm was reported to have developed a Grade 2 myelodysplastic syndrome (MDS).[11] This finding is consistent with the known risk profile of this therapeutic class. Large retrospective and prospective studies of Lutetium Lu177 dotatate have reported the incidence of therapy-related MDS and acute leukemia to be in the range of 0.7% to 2.7% with long-term follow-up.[47] This represents a small but definite risk that must be carefully considered and discussed with patients as part of the shared decision-making process, weighing the substantial benefit of controlling the primary cancer against this delayed potential complication.

5.4 Contraindications and Precautionary Measures

Although Lutetium Lu177 Edotreotide is investigational, its contraindications and precautions are expected to align with those of the approved agent, Lutetium Lu177 dotatate.

• Absolute Contraindications: Treatment is contraindicated in patients who are pregnant or may be pregnant, due to the high risk of radiation-induced harm to the fetus.[29] It is also contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min), as their inability to clear the drug would lead to excessive radiation exposure and toxicity.[50]
• Warnings and Precautions: Key warnings include the risk of radiation exposure to patients and healthcare providers, requiring appropriate handling and safety measures.[22] Other significant risks that require monitoring include myelosuppression, secondary MDS/leukemia, renal toxicity, hepatotoxicity (especially in patients with liver metastases), rare but serious hypersensitivity reactions, and the potential for neuroendocrine hormonal crisis.[44] The radiation dose to the gonads may also result in temporary or permanent infertility in both male and female patients.[22]

VI. Regulatory Landscape and Future Outlook

6.1 Current Global Regulatory Status and Expedited Designations

As of early 2025, Lutetium Lu177 Edotreotide (ITM-11) remains an investigational agent and has not yet received marketing authorization in any country.[4] However, its promising clinical data and the high unmet need in the GEP-NET population have led to the granting of several expedited regulatory designations that are intended to accelerate its development and review.

• U.S. Food and Drug Administration (FDA): The FDA has granted ITM-11 both Fast Track designation and Orphan Drug designation for the treatment of GEP-NETs.[3] Fast Track status is designed to facilitate the development of drugs that treat serious conditions and fill an unmet medical need. It allows for more frequent communication with the FDA and enables a "rolling review," where the company can submit completed sections of its New Drug Application (NDA) for review by the agency, rather than waiting until the entire application is complete.[54]
• European Medicines Agency (EMA): The EMA has also granted Orphan Drug designation to Lutetium Lu177 Edotreotide for the treatment of GEP-NETs, recognizing the rarity of the disease and providing incentives for its development.[5]
• Other Regions: Development is also proceeding in other territories, with China's National Medical Products Administration (NMPA) having granted clearance for the initiation of Phase III trials.[56]

6.2 Anticipated Submission Pathways and Commercialization

Following the positive top-line results from the pivotal COMPETE trial, the developer, ITM Isotope Technologies Munich SE, has publicly announced its clear intention to seek regulatory approval. The company plans to submit an NDA to the U.S. FDA in 2025.[11] The combination of successful Phase III data and a Fast Track designation suggests an accelerated pathway toward a potential market launch in the near future.

6.3 Future Research Directions and Unmet Needs

The clinical development strategy for Lutetium Lu177 Edotreotide extends beyond its initial indication in G1/2 GEP-NETs, aiming to maximize its therapeutic potential. The ongoing trials—COMPOSE in aggressive G2/3 GEP-NETs, LEVEL in lung/thymus NETs, and KinLET in pediatric patients—demonstrate a comprehensive lifecycle management plan to expand the drug's label to patient populations where its biological mechanism is relevant but approved options are scarce.[4]

The next frontier for PRRT research involves enhancing its efficacy through combination therapies. Radiation is a potent inducer of DNA damage, and combining PRRT with agents that inhibit DNA damage repair pathways is a rational and promising strategy. Early-phase clinical trials are already exploring the combination of Lutetium Lu177 dotatate with PARP inhibitors (e.g., olaparib) and other radiosensitizing agents, a research avenue that will likely be pursued for edotreotide as well following its approval.[59]

VII. Comparative Analysis and Positioning in the Therapeutic Armamentarium

7.1 Lutetium Lu177 Edotreotide (DOTATOC) vs. Lutetium Lu177 Dotatate (Lutathera)

The closest competitor to Lutetium Lu177 Edotreotide is Lutetium Lu177 dotatate (brand name Lutathera), which is already FDA-approved for GEP-NETs.[47] The two agents are highly similar, sharing the same DOTA chelator and 177Lu radioisotope, with the only difference being the targeting peptide: edotreotide (TOC) versus dotatate (TATE).[1]

For many years, the prevailing view in the field, based on a small 2006 comparative study in seven patients, was that dotatate was the superior peptide.[62] That study reported that 177Lu-dotatate had a longer residence time in tumors and, despite also having higher kidney retention, offered a better therapeutic index.[62] However, the landscape is now being reshaped by the high-quality evidence from the large, randomized Phase III COMPETE trial. While not a direct head-to-head comparison against Lutathera, the robust performance of Lutetium Lu177 Edotreotide against a strong active comparator (everolimus) firmly establishes it as a highly effective PRRT agent.[25] The potential advantages of the n.c.a. 177Lu used in ITM-11 may also contribute to its strong efficacy profile, a factor not present in the earlier comparison. Upon approval, clinicians may have two highly effective Lutetium-based PRRT options, with the choice potentially being driven by factors such as availability, cost, regional approvals, or subtle differences in safety that emerge from real-world evidence, rather than a definitive assumption of one peptide's superiority over the other.

7.2 Positioning Against Standard of Care: Everolimus and Chemotherapy

The current treatment algorithm for metastatic, well-differentiated GEP-NETs typically begins with somatostatin analogues (SSAs) to control symptoms and tumor growth.[64] Upon progression, several options are available, including PRRT, targeted molecular therapies like everolimus and sunitinib (for pancreatic NETs), and systemic chemotherapy.[64]

• vs. Everolimus: The COMPETE trial provides Level 1 evidence that redefines the standard of care. By demonstrating superior PFS and a more favorable safety profile, Lutetium Lu177 Edotreotide is positioned to become a preferred therapeutic option over everolimus for patients with SSTR-positive, Grade 1/2 GEP-NETs who have progressed on SSAs.[25] This result validates the superiority of the PRRT class over the mTOR inhibitor class in this specific clinical context.
• vs. Chemotherapy: Systemic chemotherapy, such as capecitabine/temozolomide (CAPTEM) or FOLFOX, is typically reserved for more aggressive, higher-grade (G2/G3), or rapidly progressing tumors, particularly those of pancreatic origin.[64] The ongoing COMPOSE trial is directly comparing Lutetium Lu177 Edotreotide to these standards of care in this higher-risk population.[20] A positive outcome in this trial would be transformative, offering a targeted, receptor-based therapy as an alternative to conventional chemotherapy, potentially with improved tolerability.

7.3 Potential Role in the GEP-NET Treatment Algorithm

Upon regulatory approval, Lutetium Lu177 Edotreotide is expected to be integrated into the GEP-NET treatment guidelines as a primary option for second-line therapy. For patients with well-differentiated, SSTR-positive, Grade 1 or 2 GEP-NETs who progress on first-line SSAs, it will represent a powerful, evidence-backed alternative to the currently approved Lutathera and a superior option to everolimus. If the COMPOSE trial proves successful, its role could expand significantly, establishing it as a key treatment for aggressive Grade 2 and 3 tumors, potentially displacing chemotherapy for a subset of these patients and offering a new standard of care in a first- or second-line setting.

VIII. Conclusion and Expert Insights

Lutetium Lu177 Edotreotide (ITM-11) has emerged as a highly promising and clinically validated targeted radiopharmaceutical. The robust, positive results from the Phase III COMPETE trial represent a significant milestone, not only for this specific agent but for the entire field of radioligand therapy. The demonstration of superior progression-free survival and a more favorable safety profile in a direct, head-to-head comparison against an established targeted molecular therapy, everolimus, provides unequivocal, high-level evidence of its clinical value in patients with Grade 1 and 2 GEP-NETs.

This achievement validates the therapeutic concept of PRRT and is poised to shift the standard of care, establishing PRRT as a preferred modality after progression on somatostatin analogues. The favorable safety profile, characterized by a lower incidence of adverse events compared to chronic oral therapy, suggests that patients may not only experience longer disease control but also a better quality of life during treatment.

While the long-term risk of secondary hematologic malignancies remains a consideration inherent to this class of therapy, it is a small risk that must be contextualized within the substantial and proven benefit of controlling a life-threatening cancer. The ongoing COMPOSE trial will be critical in defining the role of Lutetium Lu177 Edotreotide in more aggressive GEP-NETs, where the potential to replace or delay systemic chemotherapy would address a major unmet need.

With a clear regulatory pathway supported by expedited designations and an anticipated NDA submission in 2025, Lutetium Lu177 Edotreotide is on the cusp of becoming a cornerstone in the management of neuroendocrine tumors. Its development and clinical success underscore the power of precision oncology and mark a coming of age for targeted radionuclide therapies as a pivotal component of the modern oncologic armamentarium.

Works cited

1. Definition of lutetium LU 177-edotreotide - NCI Drug Dictionary, accessed September 23, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lutetium-lu-177-edotreotide
2. What is Lutetium (177Lu) edotreotide used for? - Patsnap Synapse, accessed September 23, 2025, https://synapse.patsnap.com/article/what-is-lutetium-177lu-edotreotide-used-for
3. Radionucleotide 177Lu-Edotreotide Receives Fast Track Designation From the FDA for GEP-NETs - CancerNetwork, accessed September 23, 2025, https://www.cancernetwork.com/view/radionucleotide-177lu-edotreotide-receives-fast-track-designation-from-the-fda-for-gep-nets
4. ITM-11 for Neuroendocrine Tumors (GEP-NETs), accessed September 23, 2025, https://www.itm-radiopharma.com/pipeline/itm-11-for-neuroendocrine-tumors-gep-nets/
5. Edotreotide Lutetium Lu-177 | C65H89LuN14O18S2 | CID 71467418 - PubChem, accessed September 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Edotreotide-lutetium-Lu-177
6. What is the mechanism of action of Lutetium Dotatate LU-177? - Patsnap Synapse, accessed September 23, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-lutetium-dotatate-lu-177
7. 90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans - PMC, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8469896/
8. Current clinical application of lutetium‑177 in solid tumors (Review) - PMC - PubMed Central, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11002837/
9. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? - PMC, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9659917/
10. Lutetium-177 Edotreotide: Leading-Edge Radioligand Therapy Transforming the Treatment of Neuroendocrine Tumours - Open MedScience, accessed September 23, 2025, https://openmedscience.com/lutetium-177-edotreotide-leading-edge-radioligand-therapy-transforming-the-treatment-of-neuroendocrine-tumours/
11. COMPETE Trial with ITM-11 - ITM Radiopharma, accessed September 23, 2025, https://www.itm-radiopharma.com/de/compete/
12. Lutetium Lu177 Edotreotide: Uses, Interactions, Mechanism of ..., accessed September 23, 2025, https://go.drugbank.com/drugs/DB17278
13. LUTETIUM Lu177 EDOTREOTIDE, accessed September 23, 2025, https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/lutetium-Lu177-edotreotide.pdf
14. Lutetium 177 edotreotide - ITM Solucin - AdisInsight - Springer, accessed September 23, 2025, https://adisinsight.springer.com/drugs/800048924
15. Lutetium (177Lu) edotreotide - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 23, 2025, https://synapse.patsnap.com/drug/4632dd79d2a642c6a1e7df08e72f58c1
16. EDOTREOTIDE LUTETIUM LU-177 - gsrs, accessed September 23, 2025, https://gsrs.ncats.nih.gov/ginas/app/beta/substances/RGO812Q0C8
17. Neuroendocrine Tumor Lu-177-Dotatate Therapy - StatPearls - NCBI Bookshelf, accessed September 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK587368/
18. A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE in Neuroendocrine Tumor Patients - MDPI, accessed September 23, 2025, https://www.mdpi.com/2072-6694/14/23/5792
19. Lutetium Lu 177 dotatate: Uses, Interactions, Mechanism of Action ..., accessed September 23, 2025, https://go.drugbank.com/drugs/DB13985
20. Study Details | NCT04919226 | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | ClinicalTrials.gov, accessed September 23, 2025, https://clinicaltrials.gov/study/NCT04919226
21. Study Details | NCT03049189 | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients | ClinicalTrials.gov, accessed September 23, 2025, https://www.clinicaltrials.gov/study/NCT03049189
22. Lutathera (lutetium Lu 177-dota-tate) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed September 23, 2025, https://reference.medscape.com/drug/lutathera-lutetium-lu-177-dota-tate-1000113
23. Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan ..., accessed September 23, 2025, https://d-nb.info/1332735045/34
24. Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours - PubMed, accessed September 23, 2025, https://pubmed.ncbi.nlm.nih.gov/38528164/
25. ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 Conference - ITM Radiopharma, accessed September 23, 2025, https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-presents-positive-topline-phase-3-compete-trial-data-with-nca-177lu-edotreotide-itm-11-a-targeted-radiopharmaceutical-therapy-in-patients-with-grade-1-or-2-gastroenteropancreatic-neuroendocrine-tumors-at-the-enets-2025-conference-688/
26. 177Lu-edotreotide Improves PFS in Grade 1/2 GEP-NETs in Phase 3 COMPETE Trial, accessed September 23, 2025, https://www.onclive.com/view/177lu-edotreotide-improves-pfs-in-grade-1-2-gep-nets-in-phase-3-compete-trial
27. Study Details | NCT04665739 | Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | ClinicalTrials.gov, accessed September 23, 2025, https://www.clinicaltrials.gov/study/NCT04665739
28. Lutetium Lu 177 dotatate - FDA, accessed September 23, 2025, https://www.fda.gov/media/178128/download
29. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LUTATHERA safely and eff - Novartis, accessed September 23, 2025, https://www.novartis.com/us-en/sites/novartis_us/files/lutathera.pdf
30. COMPETE Trial Data Shows 177Lu-edotreotide Improves Progression-Free Survival in SSTR-GEP-NETs | Applied Radiation Oncology, accessed September 23, 2025, https://www.appliedradiationoncology.com/articles/compete-trial-data-shows-177lu-edotreotide-improves-progression-free-survival-in-sstr-gep-nets
31. Study Details | NCT04919226 | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | ClinicalTrials.gov, accessed September 23, 2025, https://www.clinicaltrials.gov/study/NCT04919226
32. 177Lu-edotreotide Improves PFS, OS Over Everolimus for SSTR-Positive GEP-NETs, accessed September 23, 2025, https://www.gioncologynow.com/post/177lu-edotreotide-improves-pfs-os-over-everolimus-for-sstr-positive-gep-nets
33. 177Lu-edotreotide Radiopharmaceutical Therapy Prolongs PFS vs ..., accessed September 23, 2025, https://www.onclive.com/view/177lu-edotreotide-radiopharmaceutical-therapy-prolongs-pfs-vs-everolimus-in-sstr-gep-nets
34. Investigational Agent Improves PFS Vs Everolimus in Grade 1/2 GI NETs - Cancer Network, accessed September 23, 2025, https://www.cancernetwork.com/view/investigational-agent-improves-pfs-vs-everolimus-in-grade-1-2-gi-nets
35. ITM-11 succeeds in phase 3: The first big win for radiopharma? - Labiotech.eu, accessed September 23, 2025, https://www.labiotech.eu/trends-news/itm-11-radiopharmaceutical/
36. COMPETE Trial with ITM-11 - ITM Radiopharma, accessed September 23, 2025, https://www.itm-radiopharma.com/compete/
37. ITM fleshes out data for Phase III radiopharma success in neuroendocrine tumours - FirstWord Pharma, accessed September 23, 2025, https://firstwordpharma.com/story/5940158
38. COMPETE Trial Data Shows 177Lu-edotreotide Improves Progression-Free Survival in SSTR-GEP-NETs | Applied Radiology, accessed September 23, 2025, https://appliedradiology.com/articles/compete-trial-data-shows-177lu-edotreotide-improves-progression-free-survival-in-sstr-gep-nets
39. Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors. | Journal of Clinical Oncology - ASCO Publications, accessed September 23, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.TPS514
40. Pivotal phase III COMPOSE trial to compare lutetium (177Lu) edotreotide with best standard of care in patients with well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors | ECE2023 | 25th European Congress of Endocrinology | Endocrine Abstracts, accessed September 23, 2025, https://www.endocrine-abstracts.org/ea/0090/ea0090p117
41. ITM Introduces Second Phase III Trial, COMPOSE, with n.c.a. Lutetium-177-Edotreotide for Neuroendocrine Tumors at NANETS Annual Symposium 2021, accessed September 23, 2025, https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-introduces-second-phase-iii-trial-compose-with-nca-177lu-edotreotide-for-neuroendocrine-tumors-at-nanets-annual-symposium-2021-2-1-331/
42. A Study Comparing Lutetium Edotreotide with Standard Treatments in People with Digestive Neuroendocrine Tumors, accessed September 23, 2025, https://www.mskcc.org/cancer-care/clinical-trials/21-509
43. 177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial. - ASCO, accessed September 23, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT450050
44. Lutetium Lu 177 Dotatate: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed September 23, 2025, https://www.drugs.com/lutetium-lu-177-dotatate.html
45. Safety & Side Effects | LUTATHERA® (lutetium Lu 177 dotatate), accessed September 23, 2025, https://us.lutathera.com/side-effects/understanding-side-effects
46. Safety of 177Lu-DOTATATE in patients with advanced neuroendocrine tumors: Data from a U.S. expanded access program. | Journal of Clinical Oncology - ASCO Publications, accessed September 23, 2025, https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.4604
47. FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS, accessed September 23, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-treatment-gep-nets
48. Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study. | Journal of Clinical Oncology - ASCO Publications, accessed September 23, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4131
49. 177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9776442/
50. Lutathera, INN-lutetium (177Lu) oxodotreotide - European Medicines Agency, accessed September 23, 2025, https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf
51. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors | Clinical Cancer Research - AACR Journals, accessed September 23, 2025, https://aacrjournals.org/clincancerres/article/23/16/4617/80005/Long-Term-Efficacy-Survival-and-Safety-of-177Lu
52. Lutetium lu 177 dotatate (intravenous route) - Side effects & uses - Mayo Clinic, accessed September 23, 2025, https://www.mayoclinic.org/drugs-supplements/lutetium-lu-177-dotatate-intravenous-route/description/drg-20444486
53. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION LUTATHERA® lutetium (177Lu) oxodotreotide injection Sterile Solutio - Novartis, accessed September 23, 2025, https://www.novartis.com/ca-en/sites/novartis_ca/files/lutathera_scrip_e.pdf
54. FDA Grants Fast Track Designation to ITM-11 for Gastroenteropancreatic Neuroendocrine Tumors | OncLive, accessed September 23, 2025, https://www.onclive.com/view/fda-grants-fast-track-designation-to-itm-11-for-gastroenteropancreatic-neuroendocrine-tumors
55. ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs) - ITM Radiopharma, accessed September 23, 2025, https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-receives-fda-fast-track-designation-for-radionuclide-therapy-candidate-itm-11-nca-177lu-edotreotide-in-neuroendocrine-tumors-gep-nets-1-592/
56. ITM-11 - Page 1 - BioWorld, accessed September 23, 2025, https://www.bioworld.com/keywords/30807-itm-11
57. ITM targets US approval for radiopharmaceutical after Phase III ..., accessed September 23, 2025, https://www.pharmaceutical-technology.com/news/itm-targets-us-approval-for-radiopharmaceutical-after-phase-iii-readout/
58. ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - BioSpace, accessed September 23, 2025, https://www.biospace.com/press-releases/itm-announces-positive-topline-results-of-phase-3-compete-trial-with-itm-11-a-targeted-radiopharmaceutical-therapy-in-patients-with-grade-1-or-grade-2-gastroenteropancreatic-neuroendocrine-tumors-gep-nets
59. Clinical Trials Using Lutetium Lu 177 Dotatate - NCI, accessed September 23, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/lutetium-lu-177-dotatate?pn=1
60. A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors. - ASCO Publications, accessed September 23, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS4202
61. ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). - ASCO Publications, accessed September 23, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.TPS658
62. Comparison of [(177) Lu-DOTA (0), Tyr (3)] octreotate and [(177) Lu ..., accessed September 23, 2025, https://pubmed.ncbi.nlm.nih.gov/16847654/
63. Emerging innovations in theranostics for pancreatic neuroendocrine tumors - PMC, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12089376/
64. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | Journal of Clinical Oncology - ASCO Publications, accessed September 23, 2025, https://ascopubs.org/doi/10.1200/JCO.23.01529
65. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances | Journal of Nuclear Medicine, accessed September 23, 2025, https://jnm.snmjournals.org/content/60/6/721
66. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | JCO Oncology Practice, accessed September 23, 2025, https://ascopubs.org/doi/10.1200/OP-25-00133
67. Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors in - JNCCN, accessed September 23, 2025, https://jnccn.org/view/journals/jnccn/23/Supplement/article-e255012.xml?print